International journal of diabetology & vascular disease research最新文献

英文中文

Inchoate Disaster of Covid-19: A Systematic Review on Risk Factors Triggering Morbidity and Fatality Progression 新冠肺炎早期灾害：引发发病率和死亡率进展的危险因素的系统评价

International journal of diabetology & vascular disease research

Pub Date : 2021-10-30 DOI: 10.19070/2328-353x-2100051

Sumit Oberoi

引用次数: 0

Use Of Sodium - Glucose Co - Transporter - 2 Inhibitors In Hospitalized Patients With Acute Heart Failure 钠-葡萄糖共转运蛋白- 2抑制剂在急性心力衰竭住院患者中的应用

International journal of diabetology & vascular disease research

Pub Date : 2021-06-18 DOI: 10.19070/2328-353x-2100050

Nasser Mikhai

引用次数: 0

Comparison of Glycemic Control between Intensive Insulin Regimen and Continuous Subcutaneous Insulin infusion: A Meta-Analysis Report of Type-1 Diabetics from Randomized Controlled Trials 强化胰岛素方案和持续皮下胰岛素输注的血糖控制比较:一项随机对照试验1型糖尿病患者的荟萃分析报告

International journal of diabetology & vascular disease research

Pub Date : 2020-06-02 DOI: 10.1101/2020.06.01.20119693

K. Aziz, A. Othman

Achieving glycemic control and targets are challenging in type-1 diabetes management. To achieve this, intensive insulin therapy or multiple daily injections (MDI) and continuous subcutaneous insulin infusion (CSII) or pump therapy have been used in various health care settings. However, there has been a debate on their superiority. Some of researchers have recommended MDI, while others SCII. We compared MDI with CSII by a literature search. We have conducted mata-analysis for MDI and CSII on ten randomized controlled trials on 809 type-1 diabetics 809, MDI (N=394) or CSII (N=415). Heterogeneity between trials was quantified by conventional Q-statistic (Cochran heterogeneity statistic) and Higgins I2 statistic with 0-40% representing negligible heterogeneity, 30-60% moderate heterogeneity, 50-90% substantial heterogeneity and 75-100% considerable heterogeneity. tau-squared ({tau}2) was used to observe between-study random-effects variance. Meta Analyst software was used to analyze the data and to conduct meta-analysis. SPSS was used to analyze HbA1c student t-test for MDI and CSII. A random-effect analysis (( DerSimonian-Laird method) performed on ten studies found that the percentage of HbA1c was lower in patients receiving CSII compared with those receiving MDI; standardized mean difference (SMD) was 0.441 , 95% confidence interval 0.267 to 0.616, p < 0.001; equivalent to a difference of 0.39%, favoring CSII. I2 statistic was 20.9 ; {tau}2= 0.016; Q=11.378 with df = 9, indicating that heterogeneity was not significant (heterogeneity p-value = 0.251). Patients on CSII demonstrated significantly lower values (8.2 SD 0.72 versus 7.73 SD 0.72 ; p-value <0.001 respectively). This statistical and meta-analysis favors the usage of insulin pump therapy. We concluded that patient centered approach should be used while selecting the patients for insulin pump (CSII) or MDI.

在1型糖尿病管理中，实现血糖控制和目标具有挑战性。为了实现这一点，强化胰岛素治疗或每日多次注射（MDI）和连续皮下胰岛素输注（CSII）或泵治疗已在各种医疗保健环境中使用。然而，关于他们的优越性一直存在争议。一些研究人员建议使用MDI，而另一些研究人员则建议使用SCII。我们通过文献检索将MDI与CSII进行了比较。我们对809名1型糖尿病患者809、MDI（N=394）或CSII（N=415）进行了10项随机对照试验，对MDI和CSII进行了mata分析。试验之间的异质性通过常规Q统计量（Cochran异质性统计量）和Higgins I2统计量进行量化，0-40%代表可忽略的异质性，30-60%代表中度异质性，50-90%代表实质异质性，75-100%代表相当异质性。τ平方({tau}2)用于观察研究之间的随机效应方差。Meta Analyst软件用于分析数据并进行荟萃分析。SPSS用于分析HbA1c学生MDI和CSII的t检验。对10项研究进行的随机效应分析（DerSimonian-Laird法）发现，接受CSII的患者的HbA1c百分比低于接受MDI的患者；标准化平均差（SMD）为0.441，95%置信区间为0.267至0.616，p＜0.001；相当于0.39%的差异，有利于CSII。I2统计量为20.9；{tau}2=0.016；Q=11.378，df=9，表明异质性不显著（异质性p值=0.251）。接受CSII的患者表现出显著较低的值（分别为8.2 SD 0.72和7.73 SD 0.72；p值<0.001）。这项统计和荟萃分析支持使用胰岛素泵治疗。我们得出的结论是，在选择胰岛素泵（CSII）或MDI患者时，应采用以患者为中心的方法。

{"title":"Comparison of Glycemic Control between Intensive Insulin Regimen and Continuous Subcutaneous Insulin infusion: A Meta-Analysis Report of Type-1 Diabetics from Randomized Controlled Trials","authors":"K. Aziz, A. Othman","doi":"10.1101/2020.06.01.20119693","DOIUrl":"https://doi.org/10.1101/2020.06.01.20119693","url":null,"abstract":"Achieving glycemic control and targets are challenging in type-1 diabetes management. To achieve this, intensive insulin therapy or multiple daily injections (MDI) and continuous subcutaneous insulin infusion (CSII) or pump therapy have been used in various health care settings. However, there has been a debate on their superiority. Some of researchers have recommended MDI, while others SCII. We compared MDI with CSII by a literature search. We have conducted mata-analysis for MDI and CSII on ten randomized controlled trials on 809 type-1 diabetics 809, MDI (N=394) or CSII (N=415). Heterogeneity between trials was quantified by conventional Q-statistic (Cochran heterogeneity statistic) and Higgins I2 statistic with 0-40% representing negligible heterogeneity, 30-60% moderate heterogeneity, 50-90% substantial heterogeneity and 75-100% considerable heterogeneity. tau-squared ({tau}2) was used to observe between-study random-effects variance. Meta Analyst software was used to analyze the data and to conduct meta-analysis. SPSS was used to analyze HbA1c student t-test for MDI and CSII. A random-effect analysis (( DerSimonian-Laird method) performed on ten studies found that the percentage of HbA1c was lower in patients receiving CSII compared with those receiving MDI; standardized mean difference (SMD) was 0.441 , 95% confidence interval 0.267 to 0.616, p < 0.001; equivalent to a difference of 0.39%, favoring CSII. I2 statistic was 20.9 ; {tau}2= 0.016; Q=11.378 with df = 9, indicating that heterogeneity was not significant (heterogeneity p-value = 0.251). Patients on CSII demonstrated significantly lower values (8.2 SD 0.72 versus 7.73 SD 0.72 ; p-value <0.001 respectively). This statistical and meta-analysis favors the usage of insulin pump therapy. We concluded that patient centered approach should be used while selecting the patients for insulin pump (CSII) or MDI.","PeriodicalId":90543,"journal":{"name":"International journal of diabetology & vascular disease research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48087416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TRACK Implementation among Bangladeshi Population 在孟加拉国人口中实施TRACK

International journal of diabetology & vascular disease research

Pub Date : 2019-11-21 DOI: 10.19070/2328-353x-1900048

Mohiuddin Ak

million people with undetected diabetes in Bangladesh and this number will be double by 2025 [10]. Das et al. [11] reported prevalence of dyslipidemia was over 70% to both male and female subjects, which indicates the urgency of lifestyle intervention strategies to prevent and manage this important health problem and risk factor. Among 8400 stroke patients from different hospitals in Bangladesh over Abstract With the increasing burden of non-communicable diseases in low-income and middle-income countries (LMICs), biological risk factors, such as hyperglycemia, are a major public health concern in Bangladesh. Optimization of diabetes management by positive lifestyle changes is urgently required for prevention of comorbidities and complications, which in turn will reduce the cost. Diabetes had 2 times more days of inpatient treatment, 1.3 times more outpatient visits, and nearly 10 times more medications than non- diabetes patients, as reported by British Medical Journal. And surprisingly, 80% of people with this so called “Rich Man’s Disease” live in low- and middle-income countries. According to a recent study of American Medical Association, China and India collectively are home of nearly 110 million diabetic patients. The prevalence of diabetes in this region is projected to increase by 71% by 2035. Bangladesh was ranked as the 8th highest diabetic populous country in the time period of 2010-2011. In Bangladesh, the estimated prevalence of diabetes among adults was 9.7% in 2011 and the number is projected to be 13.7 million by 2045. The cost of diabetes care is considerably high in Bangladesh, and it is primarily driven by the medicine and hospitalization costs. According to Bangladesh Bureau of Statistics, in 2017 the annual average cost per T2DM was $864.7, which is 52% of per capita GDP of Bangladesh and 9.8 times higher than the general health care cost. Medicine is the highest source of direct cost (around 85%) for patients without hospitalization. The private and public financing of diabetes treatment will be severely constrained in near future, representing a health threat for the Bangladeshi population.

孟加拉国有数百万未被发现的糖尿病患者，到2025年这一数字将翻一番[10]。Das等人[11]报道，男性和女性受试者的血脂异常患病率均超过70%，这表明生活方式干预策略的紧迫性，以预防和管理这一重要的健康问题和风险因素。在孟加拉国不同医院的8400名中风患者中，随着低收入和中等收入国家（LMIC）非传染性疾病负担的增加，高血糖等生物风险因素是孟加拉国的一个主要公共卫生问题。迫切需要通过积极的生活方式改变来优化糖尿病管理，以预防合并症和并发症，从而降低成本。据《英国医学杂志》报道，糖尿病患者的住院治疗天数是非糖尿病患者的2倍，门诊就诊次数是非糖尿病病人的1.3倍，药物使用次数几乎是非糖尿病的10倍。令人惊讶的是，80%患有这种所谓的“富人病”的人生活在中低收入国家。根据美国医学会最近的一项研究，中国和印度共有近1.1亿糖尿病患者。到2035年，该地区的糖尿病患病率预计将增加71%。在2010-2011年期间，孟加拉国被列为糖尿病人口第8高的国家。在孟加拉国，2011年成年人糖尿病患病率估计为9.7%，预计到2045年这一数字将达到1370万。孟加拉国的糖尿病护理费用相当高，主要是由药品和住院费用推动的。根据孟加拉国统计局的数据，2017年，每名2型糖尿病患者的年平均费用为864.7美元，占孟加拉国人均GDP的52%，是普通医疗费用的9.8倍。对于不住院的患者来说，药品是直接费用的最高来源（约85%）。在不久的将来，糖尿病治疗的私人和公共融资将受到严重限制，这对孟加拉国人民的健康构成威胁。

{"title":"TRACK Implementation among Bangladeshi Population","authors":"Mohiuddin Ak","doi":"10.19070/2328-353x-1900048","DOIUrl":"https://doi.org/10.19070/2328-353x-1900048","url":null,"abstract":"million people with undetected diabetes in Bangladesh and this number will be double by 2025 [10]. Das et al. [11] reported prevalence of dyslipidemia was over 70% to both male and female subjects, which indicates the urgency of lifestyle intervention strategies to prevent and manage this important health problem and risk factor. Among 8400 stroke patients from different hospitals in Bangladesh over Abstract With the increasing burden of non-communicable diseases in low-income and middle-income countries (LMICs), biological risk factors, such as hyperglycemia, are a major public health concern in Bangladesh. Optimization of diabetes management by positive lifestyle changes is urgently required for prevention of comorbidities and complications, which in turn will reduce the cost. Diabetes had 2 times more days of inpatient treatment, 1.3 times more outpatient visits, and nearly 10 times more medications than non- diabetes patients, as reported by British Medical Journal. And surprisingly, 80% of people with this so called “Rich Man’s Disease” live in low- and middle-income countries. According to a recent study of American Medical Association, China and India collectively are home of nearly 110 million diabetic patients. The prevalence of diabetes in this region is projected to increase by 71% by 2035. Bangladesh was ranked as the 8th highest diabetic populous country in the time period of 2010-2011. In Bangladesh, the estimated prevalence of diabetes among adults was 9.7% in 2011 and the number is projected to be 13.7 million by 2045. The cost of diabetes care is considerably high in Bangladesh, and it is primarily driven by the medicine and hospitalization costs. According to Bangladesh Bureau of Statistics, in 2017 the annual average cost per T2DM was $864.7, which is 52% of per capita GDP of Bangladesh and 9.8 times higher than the general health care cost. Medicine is the highest source of direct cost (around 85%) for patients without hospitalization. The private and public financing of diabetes treatment will be severely constrained in near future, representing a health threat for the Bangladeshi population.","PeriodicalId":90543,"journal":{"name":"International journal of diabetology & vascular disease research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45003291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between High Sensitive-C Reactive Protein and Lipid Cardiovascular Risk Factors in Apparently Healthy Nigerian Young Adults 在表面健康的尼日利亚年轻人中，高敏c反应蛋白与脂质心血管危险因素的关系

International journal of diabetology & vascular disease research

Pub Date : 2019-08-17 DOI: 10.19070/2328-353x-1900047

Sonuga Oo, Sonuga Aa

It’s a known fact that 50% of all myocardial infarctions occur among individuals without overt hyperlipidaemia, inspite of the strong association of lipid concentrations with coronary heart disease risk (CHD) [2]. It has been shown that about 20% of all coronary events occurred in the absence of any of the traditional risk factors, such as hypertension, diabetes mellitus, hyperlipidaemia and smoking [3]. These findings raise the query if these conventional risk factors are sufficient to recognize individuals at increased risk of CHD. Therefore various non-lipid atherogenic markers have been suggested in an effort to better determine individuals at risk of CHD, these include markers of inflammation (high sensitivity C-reactive protein, interleukins, adhesion molecules, heat shock proteins); markers of fibrinolytic and haemostatic function (D-dimers, fibrinogen, thrombinantithrombin III complex); homocysteine to mention but few. Of all these non-lipid risk markers available, high sensitivity C-reactive protein (hs-CRP) is considered to be the most robust tool with test uniqueness desirable and favorable for clinical use as novel marker for CHD risk [4].

众所周知，50%的心肌梗死发生在没有明显高脂血症的人群中，尽管脂质浓度与冠心病风险密切相关[2]。研究表明，约20%的冠状动脉事件发生在没有任何传统危险因素的情况下，如高血压、糖尿病、高脂血症和吸烟[3]。这些发现提出了一个疑问，即这些传统的风险因素是否足以识别CHD风险增加的个体。因此，为了更好地确定CHD风险个体，已经提出了各种非脂质动脉粥样硬化标志物，这些标志物包括炎症标志物（高敏C反应蛋白、白细胞介素、粘附分子、热休克蛋白）；纤维蛋白溶解和止血功能的标志物（D-二聚体、纤维蛋白原、凝血酶-抗凝血酶III复合物）；同型半胱氨酸仅举几例。在所有这些可用的非脂质风险标志物中，高敏C反应蛋白（hs-CRP）被认为是最强大的工具，具有理想的测试独特性，有利于临床用作CHD风险的新标志物[4]。

{"title":"Association between High Sensitive-C Reactive Protein and Lipid Cardiovascular Risk Factors in Apparently Healthy Nigerian Young Adults","authors":"Sonuga Oo, Sonuga Aa","doi":"10.19070/2328-353x-1900047","DOIUrl":"https://doi.org/10.19070/2328-353x-1900047","url":null,"abstract":"It’s a known fact that 50% of all myocardial infarctions occur among individuals without overt hyperlipidaemia, inspite of the strong association of lipid concentrations with coronary heart disease risk (CHD) [2]. It has been shown that about 20% of all coronary events occurred in the absence of any of the traditional risk factors, such as hypertension, diabetes mellitus, hyperlipidaemia and smoking [3]. These findings raise the query if these conventional risk factors are sufficient to recognize individuals at increased risk of CHD. Therefore various non-lipid atherogenic markers have been suggested in an effort to better determine individuals at risk of CHD, these include markers of inflammation (high sensitivity C-reactive protein, interleukins, adhesion molecules, heat shock proteins); markers of fibrinolytic and haemostatic function (D-dimers, fibrinogen, thrombinantithrombin III complex); homocysteine to mention but few. Of all these non-lipid risk markers available, high sensitivity C-reactive protein (hs-CRP) is considered to be the most robust tool with test uniqueness desirable and favorable for clinical use as novel marker for CHD risk [4].","PeriodicalId":90543,"journal":{"name":"International journal of diabetology & vascular disease research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41416485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Total Adiponectin and Risk of Symptomatic Lower Extremity Peripheral Vascular Disease in Type 2 Diabetes Mellitus 总脂联素与2型糖尿病并发症状性下肢外周血管疾病的风险

International journal of diabetology & vascular disease research

Pub Date : 2019-04-09 DOI: 10.19070/2328-353X-1900046

S. Kumar

引用次数: 1

Assessment of Knowledge and Patient Counseling to the Patient with Diabetes on Diabetic Foot Care in Tertiary Care Hospital 三级医院糖尿病足护理知识评估及患者咨询

International journal of diabetology & vascular disease research

Pub Date : 2019-02-20 DOI: 10.19070/2328-353x-1900045

A. UdayaBhaskar, M. MadhanMohanRao

1 Annamacharya College of Pharmacy, Rajampet, A.P, India. JNTU, Ananthapur, A.P, India. 2 Associate Professor, Department of General Medicine, Rajiv Gandhi Institute of Medical Sciences, Kadapa, A.P, India.Dr. NTR University of Health Sciences. Vijayawada, A.P, India. 3 Associate Professor, Department of Pharmacology, Annamacharya College of Pharmacy, Rajampet, A.P, India. JNTU, Ananthapur, A.P, India.

1印度拉贾皮特安纳马查里亚药学院。JNTU，Ananthapur，A.P，印度。2印度卫生科学大学拉吉夫·甘地医学科学研究所普通医学系副教授。Vijayawada，A.P，印度。3印度拉贾皮特安纳马查里亚药学院药理学系副教授。JNTU，Ananthapur，A.P，印度。

引用次数: 2

The Antidiabetic Drug Metformin and Male Fertility: An Update 降糖药二甲双胍与男性生育能力:最新进展

International journal of diabetology & vascular disease research

Pub Date : 2019-02-07 DOI: 10.19070/2328-353X-1900014E

C. João, F. Pedro

Diabetes mellitus is a chronic disease with pandemic proportions. It has been estimated that 451 million people were diabetic in 2017 and recent statistics suggest that a worrisome 693 million people will suffer from diabetes in 2045 [1]. This metabolic disease is defined by impaired plasma glucose levels [2], which is due to insufficient insulin secretion or/and insulin resistance [3]. Thus, diminished insulin bioactivity causes a dysregulation on glucose metabolism in multiple tissues and, if not properly treated, hyperglycaemia and low insulin levels can evolve to other conditions and co-morbidities of distinct nature [4].

糖尿病是一种世界性的慢性病。据估计，2017年有4.51亿人患有糖尿病，最近的统计数据表明，到2045年，糖尿病患者将达到令人担忧的6.93亿人。这种代谢性疾病的定义是血浆葡萄糖水平受损，这是由于胰岛素分泌不足或/和胰岛素抵抗所致。因此，胰岛素生物活性降低导致多种组织中葡萄糖代谢失调，如果治疗不当，高血糖和低胰岛素水平可演变为其他疾病和不同性质的合并症。

引用次数: 1

Walking Economy is Impaired in Older Men and Women with Type 2 Diabetes. 患有 2 型糖尿病的老年男性和女性步行经济能力受损。

International journal of diabetology & vascular disease research

Pub Date : 2016-01-01 Epub Date: 2016-05-19 DOI: 10.19070/2328-353X-SI03002

A W Gardner, P S Montgomery

Objective: We compared the walking economy in older participants with and without type 2 diabetes.

Methods: Walking economy was determined in 115 older participants with type 2 diabetes and 130 older control participants without diabetes by continuously measuring oxygen uptake during a treadmill test in which the work rate was at a constant speed of 2 mph and a grade of 0% for a duration of 10 minutes. Participants also completed a Balke treadmill protocol for the determination of peak oxygen uptake, defined as the highest oxygen uptake value attained during the final work stage attained. Fractional utilization was then calculated as the walking economy oxygen uptake divided by peak oxygen uptake, expressed as a percentage.

Results: Compared to those without diabetes, participants with type 2 diabetes were older (p=0.042), had higher prevalence of men (p=0.034), obesity (p=0.010), chronic kidney disease (p=0.020), peripheral artery disease (p=0.024), and had a higher body mass index (p=0.025), and waist/hip ratio (p=0.006). After adjusting for these variables, the participants with diabetes had higher walking economy (p<0.001), fractional utilization (p<0.001), and lower peak oxygen uptake (p<0.001) than those without diabetes (p<0.001).

Conclusions: Older men and women with type 2 diabetes are less economical when they ambulate at a given speed than compared to control participants without diabetes, independent of their greater co-morbid burden. The impaired walking economy in the diabetic participants is further magnified by their lower aerobic fitness, thereby leading to a higher fractional utilization of oxygen consumed during a given walking task.

目的我们比较了患有和未患有 2 型糖尿病的老年参与者的步行经济性：对 115 名患有 2 型糖尿病的老年参与者和 130 名未患糖尿病的老年对照组参与者进行了步行经济性测定，方法是在跑步机测试中连续测量摄氧量，测试中的工作速度为每小时 2 英里，坡度为 0%，持续时间为 10 分钟。参与者还完成了巴尔克跑步机方案，以确定峰值摄氧量，峰值摄氧量的定义是在最后工作阶段达到的最高摄氧量值。然后以百分比表示，计算出步行经济吸氧量除以峰值吸氧量的利用率：与非糖尿病患者相比，2 型糖尿病患者的年龄更大（p=0.042），男性（p=0.034）、肥胖（p=0.010）、慢性肾病（p=0.020）、外周动脉疾病（p=0.024）的发病率更高，体重指数（p=0.025）和腰围/臀围比（p=0.006）也更高。对这些变量进行调整后，糖尿病患者的步行经济性更高（p结论：患有 2 型糖尿病的老年男性和女性与未患糖尿病的对照组参与者相比，在一定速度下行走的经济性较差，这与他们的并发症负担较重无关。糖尿病患者较低的有氧运动能力进一步加剧了他们行走的经济性，从而导致他们在特定行走任务中消耗的氧气利用率更高。

{"title":"Walking Economy is Impaired in Older Men and Women with Type 2 Diabetes.","authors":"A W Gardner, P S Montgomery","doi":"10.19070/2328-353X-SI03002","DOIUrl":"10.19070/2328-353X-SI03002","url":null,"abstract":"Objective: We compared the walking economy in older participants with and without type 2 diabetes.Methods: Walking economy was determined in 115 older participants with type 2 diabetes and 130 older control participants without diabetes by continuously measuring oxygen uptake during a treadmill test in which the work rate was at a constant speed of 2 mph and a grade of 0% for a duration of 10 minutes. Participants also completed a Balke treadmill protocol for the determination of peak oxygen uptake, defined as the highest oxygen uptake value attained during the final work stage attained. Fractional utilization was then calculated as the walking economy oxygen uptake divided by peak oxygen uptake, expressed as a percentage.Results: Compared to those without diabetes, participants with type 2 diabetes were older (p=0.042), had higher prevalence of men (p=0.034), obesity (p=0.010), chronic kidney disease (p=0.020), peripheral artery disease (p=0.024), and had a higher body mass index (p=0.025), and waist/hip ratio (p=0.006). After adjusting for these variables, the participants with diabetes had higher walking economy (p<0.001), fractional utilization (p<0.001), and lower peak oxygen uptake (p<0.001) than those without diabetes (p<0.001).Conclusions: Older men and women with type 2 diabetes are less economical when they ambulate at a given speed than compared to control participants without diabetes, independent of their greater co-morbid burden. The impaired walking economy in the diabetic participants is further magnified by their lower aerobic fitness, thereby leading to a higher fractional utilization of oxygen consumed during a given walking task.","PeriodicalId":90543,"journal":{"name":"International journal of diabetology & vascular disease research","volume":"2016 Suppl 3","pages":"7-12"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376089/pdf/nihms-811957.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34882249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prediabetes: The Variation between HbA1c and Fasting Plasma Glucose. 糖尿病前期:HbA1c与空腹血糖的变化。

International journal of diabetology & vascular disease research

Pub Date : 2015-01-01 Epub Date: 2015-06-05 DOI: 10.19070/2328-353X-SI02001

K A M White, S Daneshvari, J Lilyquist, L Luo, L E Steffen, A Bivin, N Gurule, G M Ducasa, S M Torres, R Lindeman, S Sankarappan, M Berwick

Purpose: The prevalence of Diabetes Type 2 is on the rise internationally. Currently, Fasting Plasma Glucose (FPG) and HbA1c are both used to determine if an individual is diabetic or prediabetic. We aimed to describe the prevalence of diabetes, prediabetes, and glycemic control in a population-based sample of elderly Hispanic and non-Hispanic White participants in New Mexico.

Methods: To do this, we compared HbA1c with FPG using Chi-Square analysis across gender and ethnicity to provide information for future health care policy. We also performed non-parametric regression using a locally weighted smoothing technique to investigate the relationship between FPG and HbA1c levels.

Results: Our analysis identifies a large variation between the sensitivity of HbA1c and FPG in the identification of both prediabetes and diabetes. Interestingly, 95% of diabetics defined by FPG are also defined by HbA1c, representing overlap between the two measures. When comparing the prevalence of prediabetes between the two measures, the overlap of FPG with HbA1c was only 30% and HbA1c identifies more individuals as prediabetic than FPG. Prevalence of diabetes was also higher when defined by HbA1c compared to FPG and the overall agreement between HbA1c and FPG appears to be poor particularly by sex and ethnicity (K=0.22-0.34). Glycemic control was poor overall with Hispanics displaying a larger amount of uncontrolled diabetes.

Conclusion: We compared HbA1c and FPG by gender and ethnicity and showed both measures of diabetes differ in their sensitivity across ethnic groups. Our results suggest that using HbA1c, rather than FPG, results in higher rates of prediabetes and diabetes, a finding with numerous implications for health care practice.

目的:2型糖尿病的患病率在国际上呈上升趋势。目前，空腹血糖(FPG)和糖化血红蛋白(HbA1c)都被用来判断一个人是否患有糖尿病或糖尿病前期。我们的目的是描述新墨西哥州老年西班牙裔和非西班牙裔白人参与者中糖尿病、前驱糖尿病和血糖控制的患病率。方法:为了做到这一点，我们使用跨性别和种族的卡方分析比较了HbA1c和FPG，为未来的卫生保健政策提供信息。我们还使用局部加权平滑技术进行了非参数回归，以研究FPG和HbA1c水平之间的关系。结果:我们的分析发现HbA1c和FPG在识别糖尿病前期和糖尿病方面的敏感性存在很大差异。有趣的是，95%由FPG定义的糖尿病患者也由HbA1c定义，这代表了两种测量之间的重叠。当比较两种测量之间的前驱糖尿病患病率时，FPG与HbA1c的重叠仅为30%，HbA1c比FPG识别更多的个体为前驱糖尿病。与FPG相比，HbA1c定义的糖尿病患病率也更高，HbA1c和FPG之间的总体一致性似乎较差，特别是性别和种族(K=0.22-0.34)。血糖控制总体较差，西班牙裔糖尿病患者的未控制糖尿病患者较多。结论:我们将HbA1c和FPG按性别和种族进行比较，发现这两种糖尿病指标在不同种族间的敏感性存在差异。我们的研究结果表明，使用HbA1c而不是FPG会导致更高的糖尿病前期和糖尿病发病率，这一发现对医疗保健实践具有许多意义。

{"title":"Prediabetes: The Variation between HbA1c and Fasting Plasma Glucose.","authors":"K A M White, S Daneshvari, J Lilyquist, L Luo, L E Steffen, A Bivin, N Gurule, G M Ducasa, S M Torres, R Lindeman, S Sankarappan, M Berwick","doi":"10.19070/2328-353X-SI02001","DOIUrl":"https://doi.org/10.19070/2328-353X-SI02001","url":null,"abstract":"Purpose: The prevalence of Diabetes Type 2 is on the rise internationally. Currently, Fasting Plasma Glucose (FPG) and HbA1c are both used to determine if an individual is diabetic or prediabetic. We aimed to describe the prevalence of diabetes, prediabetes, and glycemic control in a population-based sample of elderly Hispanic and non-Hispanic White participants in New Mexico.Methods: To do this, we compared HbA1c with FPG using Chi-Square analysis across gender and ethnicity to provide information for future health care policy. We also performed non-parametric regression using a locally weighted smoothing technique to investigate the relationship between FPG and HbA1c levels.Results: Our analysis identifies a large variation between the sensitivity of HbA1c and FPG in the identification of both prediabetes and diabetes. Interestingly, 95% of diabetics defined by FPG are also defined by HbA1c, representing overlap between the two measures. When comparing the prevalence of prediabetes between the two measures, the overlap of FPG with HbA1c was only 30% and HbA1c identifies more individuals as prediabetic than FPG. Prevalence of diabetes was also higher when defined by HbA1c compared to FPG and the overall agreement between HbA1c and FPG appears to be poor particularly by sex and ethnicity (K=0.22-0.34). Glycemic control was poor overall with Hispanics displaying a larger amount of uncontrolled diabetes.Conclusion: We compared HbA1c and FPG by gender and ethnicity and showed both measures of diabetes differ in their sensitivity across ethnic groups. Our results suggest that using HbA1c, rather than FPG, results in higher rates of prediabetes and diabetes, a finding with numerous implications for health care practice.","PeriodicalId":90543,"journal":{"name":"International journal of diabetology & vascular disease research","volume":"Suppl 2 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.19070/2328-353X-SI02001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35073704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

International journal of diabetology & vascular disease research

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀